Improving Latent Tuberculosis (TB) Diagnosis in Thai Children

HIV Infections Clinical Trial

— TB Px  

Official title:

Improving the Diagnosis and Management of Latent Tuberculosis in Thai Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00947609
• Other study ID #: SEARCH TB Px
• Status: Completed
• Phase: N/A
• First received: July 27, 2009
• Last updated: June 5, 2012
• Start date: August 2009
• Est. completion date: December 2011

Study information

• Verified date: June 2012
• Source: South East Asia Research Collaboration with Hawaii
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: Ministry of Public HealthUnited States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The study is a prospective study to improve the diagnosis and management of latent TB in HIV-infected and HIV uninfected children in Thailand. The objectives are to assess the sensitivity and specificity of IGRAs (T-Spot®.TB, a T-cell-based assay, and QuantiFERON®-TB Gold In-tube, a whole blood assay), TST, and a refined symptom-based questionnaire in diagnosing latent TB in 166 HIV-infected and HIV uninfected children in Thailand, and to evaluate the influence of age, nutritional and immune status on children's response to the IGRAs. These children will be screened for TB with a detailed TB contact history, symptom-based questionnaire, physical examination, TST, chest radiograph (and abdominal ultrasound for those with abdominal symptoms), IGRAs, and clinical specimens for acid fast bacilli stain and culture. A diagnostic algorithm will be generated using the combination of test modalities with the highest sensitivity and specificity results.

Description:

Study Objectives

• To compare the utility of IGRAs, T-Spot®.TB and QuantiFERON®-TB Gold In-Tube, and TST for screening of latent TB in HIV-infected children

• To compare these different screening modalities in HIV-infected children to HIV uninfected children

• To assess the influence of age, nutritional and immune status, prior BCG and TST status on children's response to IGRAs

• To assess the prognostic value of IGRAs vs. TST in predicting development of active TB in children over 9 months

Research questions:

Primary:

What is the sensitivity and specificity of IGRAs and TST in screening for latent TB in HIV-infected and HIV uninfected children in Thailand?

Secondary:

How do age, nutritional and immune status, prior BCG and PPD status influence children's response to IGRAs? What is the prognostic value of IGRAs vs. TST in predicting development of active TB in children over 9 months?

This is a prospective cohort study conducted at two sites in Bangkok, Thailand: HIV Netherlands Australia Thailand (HIV-NAT) Clinic/Chulalongkorn Hospital and Queen Sirikit National Institute of Child Health.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 158
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 2 Months to 16 Years

Eligibility

Inclusion Criteria:

1. Have close contact with a person > 15 years of age who had active pulmonary (± extrapulmonary), sputum AFB positive TB (household member or non-household member with contact > 120 hours/month) during the past year

2. Are between the ages of 2 months and 16 years

3. Parents or caregivers provide informed consent to participate

4. Provide child assent for children aged = 7 years

Exclusion Criteria:

1. Child and/or parent/caregiver who refuse study participation

2. Are currently receiving antituberculosis medications for TB disease

3. Have recently been diagnosed with active TB within past 6 months

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• HIV Infections
• Latent Tuberculosis
• Tuberculosis

Locations

Country	Name	City	State
Thailand	HIV Netherlands Australia Thailand (HIV-NAT) Research Organization	Bangkok
Thailand	Queen Sirikit National Institute of Child Health	Bangkok

Sponsors (5)

Lead Sponsor	Collaborator
South East Asia Research Collaboration with Hawaii	Columbia University, HIV Netherlands Australia Thailand Research Collaboration, New York Blood Center, Queen Sirikit National Institute of Child Health

Country where clinical trial is conducted

Thailand,